Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 9:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 810 matching trials from the live ClinicalTrials.gov search.
Filters: "pulmonary hypertension" Condition: Hypertension Clear all
Completed Phase 3 Interventional Results available

The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH

NCT00159861
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Sildenafil citrate
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
16 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
33
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 11, 2026, 9:03 AM EDT
Completed Phase 1 Interventional

Phase I Trial of Inhaled Nitric Oxide to Treat Acute Pulmonary Embolism

NCT00848731
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
nitric oxide
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 11, 2026, 9:03 AM EDT
Terminated Phase 3 Interventional Results available

Pravastatin to Prevent Preeclampsia

NCT03944512
View directory record Official record
Conditions
Preeclampsia, Obstetric Labor Complications, Hypertension in Pregnancy
Interventions
Pravastatin, Placebo
Drug · Other
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
16 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • Chicago, Illinois • New York, New York + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 11, 2026, 9:03 AM EDT
Terminated Phase 3 Interventional Results available

Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)

NCT00795639
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions
Sitaxsentan, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years to 80 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
32
States / cities
Fountain Valley, California • Mather, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 11, 2026, 9:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prognostic Indicators as Provided by the EPIC ClearView

NCT01476995
View directory record Official record
Conditions
Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation, Hypertension, Pyelonephritis, Acute Renal Failure, Renal Failure, Viral Hepatitis, Alcoholic Hepatitis, Steatohepatitis, Cirrhosis, Asthma, COPD, Bronchitis, Emphysema, Pneumonia, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Diverticulitis, Peptic Ulcer Disease, Irritable Bowel Syndrome, Cholecystitis, Pancreatitis, Malabsorption Disorders, Celiac Sprue, Diabetes
Interventions
Not listed
Lead sponsor
Epic Research & Diagnostics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Oct 11, 2026, 9:03 AM EDT
Completed No phase listed Observational

The Expression and Significance of MiRNA

NCT00806312
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
Megan Ballinger
Other
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 11, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

Effects of DHEA in Pulmonary Hypertension

NCT03648385
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
DHEA tablet, Placebo
Drug · Other
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 11, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)

NCT04896008
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sotatercept, Placebo
Drug · Other
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years to 75 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
26
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 11, 2026, 9:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Social Work Intervention Focused on Transitions

NCT02232126
View directory record Official record
Conditions
Study Focus: 30-day Rehospitalizations Among At-risk Older Adults Randomized to a Social Work-driven Care Transitions Intervention, Heart Disease, Diabetes, Hypertension, Cancer, Depression, Asthma, Chronic Heart Failure, Chronic Obstructive Pulmonary Disease, Stroke
Interventions
SWIFT home intervention
Other
Lead sponsor
University of Southern California
Other
Eligibility
65 Years to 110 Years
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
Los Angeles, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 11, 2026, 9:03 AM EDT
Active, not recruiting Phase 4 Interventional

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

NCT05203510
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Parenteral Treprostinil, Oral Treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
28
States / cities
Phoenix, Arizona • Fresno, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 11, 2026, 9:03 AM EDT
Completed Phase 4 Interventional Results available

Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).

NCT00878878
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Dextrose
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Elliott, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2012 · Synced Oct 11, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)

NCT02664558
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
ubenimex, placebo
Drug · Other
Lead sponsor
Eiger BioPharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
28
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 11, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Role of Endothelin in Pulmonary Hypertension

NCT00759408
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
BQ-123
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 11, 2026, 9:03 AM EDT
Completed No phase listed Observational Results available

Novel Cardiac Magnetic Resonance Imaging to Define a Unique Restrictive Cardiomyopathy in Sickle Cell Disease

NCT02410811
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Cardiac magnetic resonance imaging (CMR)
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 11, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients

NCT00792571
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Beraprost Sodium Modified Release
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Torrance, California • Pittsburgh, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 11, 2026, 9:03 AM EDT
Recruiting Not applicable Interventional

Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia (FETO)

NCT03138863
View directory record Official record
Conditions
Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia, Pulmonary Artery Hypertension
Interventions
BALT GoldbBAL2 Detachable Balloon, Catheter System
Device
Lead sponsor
Rodrigo Ruano
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Miami, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 11, 2026, 9:03 AM EDT
Completed Not applicable Interventional Results available

Effect of Sildenafil on Diffusion Capacity in Patients With PH and Parenchymal Lung Disease

NCT01948518
View directory record Official record
Conditions
Diffuse Parenchymal Lung Disease, Pulmonary Hypertension
Interventions
Oral sildenafil 20 mg
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Oct 11, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Subcutaneous Elafin in Healthy Subjects

NCT03522935
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Elafin, Placebo
Drug
Lead sponsor
Roham T. Zamanian
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 11, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument

NCT01841762
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
81
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 11, 2026, 9:03 AM EDT
Completed Phase 3 Interventional

PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension

NCT00125918
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
tadalafil, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Tucson, Arizona • Minneapolis, Minnesota • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 21, 2008 · Synced Oct 11, 2026, 9:03 AM EDT
Completed Not applicable Interventional Results available

Rural Home Hospital: Proof of Concept

NCT04531280
View directory record Official record
Conditions
Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions
Home hospital care
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 11, 2026, 9:03 AM EDT
Withdrawn Phase 2 Interventional

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

NCT02603068
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Fibrosis
Interventions
Oral treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Oct 11, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension

NCT02279160
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
APD811, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 11, 2026, 9:03 AM EDT
Recruiting Phase 2 Interventional

Bioenergetic Effect of Pioglitazone in CLD-PH

NCT06336798
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Hypertension Due to Lung Diseases
Interventions
Pioglitazone 30mg, Placebo, Labs
Drug · Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 11, 2026, 9:03 AM EDT